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Background: Consumer surveys provide information on effectiveness and side effects of medical interventions in
routine clinical care. A report of fibromyalgia syndrome (FMS) consumers has not been carried out in Europe.
Methods: The study was carried out from November 2010 to April 2011. Participants diagnosed with FMS rated the
effectiveness and side effects of pharmacological and non-pharmacological FMS interventions on a 0 to 10 scale,
with 10 being most efficacious (harmful). The questionnaire was distributed by the German League for people with
Arthritis and Rheumatism and the German Fibromyalgia Association to their members and to all consecutive FMS
patients of nine clinical centers of different levels of care.
Results: 1661 questionnaires (95% women, mean age 54 years, mean duration since FMS diagnosis 6.8 years) were
analysed. The most frequently used therapies were self-management strategies, prescription pain medication and
aerobic exercise. The highest average effectiveness was attributed to whole body and local warmth therapies,
thermal bathes, FMS education and resting. The highest average side effects were attributed to strong opioids, local
cold therapy, gamma-amino-butyric acid analogues (pregabalin and gabapentin), tramadol and opioid transdermal
systems.
Conclusion: The German fibromyalgia consumer reports highlight the importance of non-pharmcological therapies
in the long-term management of FMS, and challenges the strong recommendations for drug therapies given by
FMS-guidelines.
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The key symptoms of fibromyalgia syndrome (FMS) are
chronic widespread pain, unrefreshed sleep, cognitive
dysfunction and fatigue [1,2]. Patients often report high
disability levels and poor quality of life along with exten-
sive use of medical care [3,4]. The prevalence of FMS
was 2.9-3.8% in the general population of five European
countries [5,6]. FMS can be diagnosed in clinical care by
the American College of Rheumatology 2010 preliminary
diagnostic criteria [1] and in surveys by the fibromyalgia
survey diagnostic criteria [7].* Correspondence: whaeuser@klinikum-saarbruecken.de
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reproduction in any medium, provided the orThe definitive etiology and pathophysiology of FMS
are unknown [8]. A great variety of pharmacological and
non-pharmacological therapies are offered to and used
by patients to relieve symptoms [9]. Evidence-based
guidelines aim to guide patients and health care provi-
ders in the choice of treatment options [10-12]. These
guidelines rely on randomised controlled trials of
pharmacological and non-pharmacological therapies.
However, the external validity of RCTs in FMS is limited:
Most studies excluded patients with inflammatory
rheumatic diseases and severe mental disorders and
were conducted in research and university centers [13].
Consumer reports, in which patients assess the effective-
ness and side effects of interventions, can supplement
the results of RCTs, because participants are not
excluded because of comorbidities [13]. The US National
Fibromyalgia Association (NFA) conducted an internetLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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effectiveness of FMS-treatments in 2005. Side effects
were not assessed [14].
Given the limited external validity of RCTs in FMS, we
conducted the first European FMS consumer reports on




Participants of the study were recruited by the two
largest German FMS-self help organisations and nine
clinical institutions. The specialties of the clinical
institutions were pain medicine and psychotherapy
(N = 3), rheumatology (N = 2), complementary and al-
ternative medicine (N = 2), physical therapy (N = 1)
and pain therapy (N = 1). The settings were outpatient
(N = 6), inpatient (N = 2) and day clinic (N = 1). The
levels of care were secondary (N = 6) and tertiary care
(N = 2) and rehabilitation (N = 1).
Inclusion- and exclusion criteria
Members of the self-help organisations had to report that
the diagnosis of FMS had been established by a physician.
Because there is no gold standard for the clinical diagno-
sis of FMS [15], the physicians of the participating study
centers were free in their choice of FMS-diagnostic cri-
teria. Patients who were not able to read German and
patients with a FMS-diagnosis of <1 month’s duration
were excluded. There were no other exclusion criteria.
Procedure
Clinical institutions
From November 1, 2010 to April 30, 2011 all consecu-
tive patients with an established diagnosis of FMS at the
participating study centres were asked by the physicians
of these centres to take part in the study. The question-
naires were handed out by the physicians of the centres
with a standardized letter explaining the focus of the
study. The questionnaires were returned by the patients
in a closed and anonymous envelope and kept away
from the charts. At the end of the study the question-
naires were sent to the coordinating study centre.
Self-help organisations
The package of questionnaires was sent by the central
office of the German League for people with Arthritis
and Rheumatism to their regional offices with the re-
quest that the leaders of the local self-help groups dis-
tribute the questionnaires to their members during
group meetings. The German Fibromyalgia Association
included the package in the 4/2010 issue of its member
journal „Optimist,“which was sent out by post to all
members. Patients returned the questionnaires by postat their own cost to the central office. In addition, the
questionnaires were available on the homepages of both
self-help organisations. After downloading and complet-
ing the completed questionnaires, they were sent by
mail, fax or email to the central offices. Employees of
both central offices removed personal identifying infor-
mation and sent the questionnaires to the coordinating
study centre.
The participants (investigators and patients) of the
study did not receive any reimbursement or compensa-
tion for participation.
Survey questionnaires
Demographic data and medical data were assessed by a
questionnaire used in a previous multicenter German
FMS-study [16].
The questionnaire “Benefits and harms of FMS-
therapies” was delevoped by the heads of the clinical
centers taking part in the study and by the directors of
the two FMS self-help organisations. Similar to the
NFA – questionnaire [14], survey participants were
asked to "indicate whether you currently use any of the
following interventions for FMS and if so, whether each
helps to relieve your FMS symptoms". Moreover, the
patients were asked if they had used these interventions
in the past. Respondents rated the effectiveness (relief of
symptoms) and harms (side effects) of each intervention
used in the present or past on a 0 to 10 scale, with 10
being most effective (harmful). The interventions were
listed in different sections: Self-management strategies
(exercise, resting, physical modalities), psychological
therapies, drugs and complementary/alternative medi-
cine (CAM) (a copy of the questionaire is available on
request). Face validity and understandability of the ques-
tionnaire were qualitatively validated by four clinicians
(rheumatology, pain medicine, psychosomatic medicine)
and 10 patients (integrative medicine, pain medicine)
not involved in the study. Eight questioniare items were
modified according to the validation reports.
The 4-item Patient Health Questionnaire-4 (PHQ-4) is
an ultra-brief self-report questionnaire that consists of a
2-item depression scale (PHQ-2) and a 2-item anxiety
scale (GAD-2). A score of ≥ 3 on the depression subscale
represents a reasonable cut-point for identifying poten-
tial cases of major depression or other depressive disor-
ders; a score of ≥3 on the anxiety subscale represents a
reasonable cut-point for generalized anxiety, panic, so-
cial anxiety, and posttraumatic stress disorders [17]. We
used the validated German version of the PHQ 4 [18].
Statistical analysis
The data were entered by four pairs of study assistants
into a preconstructed data sheet. The entering of data
was randomly checked by two authors, and further
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Missing values were not replaced. Descriptive statistics
were performed by Winstat for Excel (R. Fitch Software,
Bad Krozingen, Germany, 2010).Ethics
Study investigators respected the requirements of data
protection and medical professional secrecy. The study
was approved by the ethical committee of the Ludwig
Maximilian Universität München.Results
Study participants
There were no data available about how many patients
contacted by the self-help organisation declined toTable 1 Demographic and clinical characteristics of the
study participants (N= 1661)





Age 1650 54.3 (9,8; 19,86)
Family situation
Living with a partner 1249 (75.8)
Living alone 377 (22.9)




Secondary school 675 (41.0)






Sick leave 131 (8.0)
Applying for disability pension 150 (9.1)
Without job 21 (1.3)




1634 16.6 (11.1; 0.25-61)
Years since diagnosis of
fibromyalgia syndrome




* Note: The discrepancies between the number of persons included in the
study and the number of persons in the following rows are due to missing
items.participate in the study. The German League for people
with Arthritis and Rheumatism estimated that 10,000 of
their members were FMS patients. The German Fibro-
myalgia Association indicated that 4,000 members have
FMS.
123 patients of the clinical samples did not meet the
primary inclusion criteria and 40 of the contacted
patients refused to take part in the study. 1,661 ques-
tionnaires were analysed. The total study sample was
composed mainly of middle-aged women with long
durations of CWP and time from FMS diagnosis (see
Table 1).
1411 (85.5%) participants met the fibromyalgia survey
diagnostic criteria [7]. 276/1351 (20.4%) participants
reported a diagnosis of an inflammatory rheumaticTable 2 Currently used types of management strategies





(e.g. lying down, relaxing)
1121/1496 81.6
Prescription pain medications






Muscle relaxants 298 18.5
Weak opioids 262 17.6
Strong opioids 119 8.4
Anticonvulsants (Pregabalin, gabapentin) 104 7.6
Self-management, physical modalities
(Local and whole body warmth,
thermal bathes))
1038/1549 67.0
Aerobic exercise (Aquatic exercise,
walking/jogging, swimming, cycling)
902/1555 58.0
Physical therapies, manual (Chirotherapy,
osteopathy, massage, lymph drainage,
physiotherapy)
853/1619 52.7
CAM – medication (Homeopathy, dietary
supplements, vitamins- and mineral
nutrients, other CAM-drugs)
527/1497 35.2
CAM - diet (change of diet, elimination
diet, fasting cure, vegetarian diet)
513/1484 34.6
Physical therapies, technical (Acupuncture,






Relaxation training (Autogenic training,
progressive muscle relaxation)
357/1542 23.1
CAM - movement (Yoga, Tai Chi,Qi-Gong,
dance- and music therapy)
278/1510 18,4
Psychological therapies (Biofeedback, hypnosis) 19/1423 1.3
* Note: The discrepancies between the number of persons in the different
rows are due to missing items.
Table 4 Top ten of most harmful (side effects)









1 Strong opioids 133; 5.4 (3.6) 49 (36.8)
2 Local cold therapy 367; 5.1 (4.1) 148 (40.3)
3 Anticonvulsants
(Pregabalin, Gabapentin)
198; 5.0 (3.7) 69 (34.9)
4 Tramadol 365; 4.8 (3.6) 110 (30.1)
5 Transdermal opioids 115; 4.7 (3.8) 35 (30.4)
6 Duloxetine 192; 4.5 (3.7) 56 (29.2)
7 Amitriptyline 598; 4.5 (3.5) 157 (26.3)
8 Tramadol combined
with paracetamol
82; 4.3(3.7) 20 (24.4)
9 Tilidine 262; 4.3 (3.5) 65 (24.8)
10 Whole body cold therapy 244; 4.1 (4.2) 79 (32.4)
* Note: The discrepancies between the number of persons in the different
rows are due to missing items.
The ratings of side effects of all management strategies are available on
request.
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the PHQ 4 depression scale and 889/1633 (54.4%)
scored>= 3 on the PHQ 4 anxiety scale.
Most frequently used interventions
The most frequently used types of current interventions
were self-management strategies, prescription pain
medication and aerobic exercise (see Table 2).
Effectiveness and side effects
The highest average effectiveness was attributed to
whole body warmth therapies (biosauna, infrared cabin,
warmth bathes), thermal bathes, FMS education and
resting and local warmth therapy (see Table 3). The
highest average side effects were attributed to strong
opioids, local cold therapy, gamma-amino-butyric acid
analogues (GABA) (pregabalin, gabapentin), tramadol
and opioid transdermal opioid systems (see Table 4).
The frequency of use and the perceived benefits and
harms of some therapies depended on some demo-
graphic (e.g. member of self-help group) and some clinical
characteristics (e.g. comorbid inflammatory rheumatic dis-
ease and probable depressive disorder) (Jung et al.,
submitted).
Discussion
Summary of main results
We conducted the first European FMS consumer
reports. 1661 FMS patients participated. In contrast to
randomised controlled trials, patients with comorbid in-
flammatory rheumatic diseases and mental disordersTable 3 Top ten of most effective management strategies








1 Whole body warmth
therapy
984; 7.1 (2.6) 507 (51.5)
2 Thermal bathes 699; 7.0 (2.7) 354 (50.6)
3 FMS education 649; 6.8 (2.7) 304 (46.8)
4 Resting 1296; 6.6 (2.5) 519 (40.1)
5 Local warmth therapy 1088; 6.6 (2.5) 452 (41.6)
6 Lymph drainage 481; 6.4 (2.8) 197 (41.0)
7 Functional training ** 781; 6.2 (2.7) 271 (34.7)
8 Warm bathes 681; 6.1 (2.9) 250 (36.7)
9 Osteopathy 445; 6.0 (3.1) 177 (38.8)
10 Dance therapy 159; 6.0 (2.9) 60 (37.7)
* Note: The discrepancies between the number of persons in the different
rows are due to missing items.
** Combination of land- and water-based exercises (stretching, aerobic
exercise) guided by a licensed trainer; the costs are covered for two years by
German health insurance companies if prescribed by a physician.
The efficacy ratings of all management strategies are available on request.were included. Self-management strategies were the
most frequently types of interventions currently used by
the participants. Participants attributed the highest ef-
fectiveness to the relief of FMS-symptoms by non-
pharmacological treatments (warmth therapy, balneo-
therapy, education). In contrast, strong opioids and
GABA-analogues (pregabalin, gabapentin) were asso-
ciated with the strongest side effects.
Comparison with other studies
The most frequently used therapies of the German and
of the NFA-study [15] were resting and distraction. Aer-
obic exercise, prescribed analgesics and strength training
were more frequently used by German compared to US
survey participants. Antidepressants, prescribed sleep
medication, nutritional supplements, massage and cold
therapy were more frequently used by US than by Ger-
man consumers. Both US and German survey partici-
pants indicated that resting, heat modalities and
massage were the most effective therapies. German
FMS-consumers reported less benefits from drug ther-
apies than US American FMS-consumers (see Table 5).
Internet-based consumer reports can provide add-
itional information on the effectiveness and side effects
of therapies. “PatientsLikeme” is a social networking
health internet webpage that enables its members to
share conditions, treatment, and symptom information
in order to monitor their health over time and learn
from real-world outcomes. Patients can evaluate the ef-
fectiveness and type of side effects of drug therapies. 2084
(12%) of the FMS-patients registered in PatientsLikeme
Table 5 Comparison of selected management strategies
currently used by US- (members of the National
Fibromyalgia Association) (N= 2596) [14] and German
FMS-consumers (N=1661) (in descending order of frequency
according to US-survey) [14] (0 =no effectiveness or harm;
10 =maximum effectiveness or harm)








Resting 86; 6.3 (2.5) 82; 6.6 (2.5)
Distraction 80; 4.7 (2.5) 86; 5.8 (2.3)
Heat modalities 74; 6.3 (2.3) 54; 6.6 (2.5)
Nutritional supplements 68; 3.8 (2.8) 20; 4.0 (3.0)
Prescription pain medication 66; 6.3 (2.4) 82; 4.8 (2.3)
Gentle walking 64; 4.6 (2.6) 80; 5.9 (2.9)
Prescription antidepressants 63; 6.2 (2.8) 46; 4.1 (3.1)
Stretching 62; 5.4 (2.6) 44; 5.8 (2.6)
Prescription sleep medication 52; 6.5 (2.7) 7; 5.0 (3.0)
Relaxation 47; 5.1 (5.5) 49; 5.9 (2.7)
Massage 43; 6.1 (2.8) 25; 6.0 (2.8)
Aerobic exercise 32; 5.0 (3.0) 58; 5.4 (2.7)
Cold therapy 30; 4.8 (2.8) 10; 4.0 (3.5)
TENS 21; 4.3 (2.9) 17; 3.5 (2.8)
Strength training 18; 4.3 (2.9) 39; 5.3 (2.7)
Pain clinic 17; 4.8 (3.1) 4; 5.9 (3.3)
Acupuncture 15; 4.5 (3.5) 11; 4.4 (3.3)
Cognitive-behavioral therapy 8; 4.3 (3.2) 11; 5.5 (3.0)
Hypnosis 3; 2.5 (2.9) 1; 4.5 (3.3)
* Details are available on request.
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(11%) with pregabalin. The majority of the patients attrib-
uted a moderate efficacy to all of these drugs. 542 FMS-
patients reported discontinuation of duloxetine and 687 to
stopped pregabalin because of adverse effects [19].Limitations
Methodological problems such as retrospective design,
lack of a control group, unspecified time frame, global
assessment of effectiveness and side effects and lack of
other assessment instruments than self-reports are in-
herent in effectiveness studies in a natural design such
as used in the consumer reports [20].
Additional major methodology limitations of the design
of this study were as follows: the different modalities of
the distribution and recollection of the questionnaires led
to a relevant number of missing data; the unknown re-
sponse rate of the participants recruited by self-help orga-
nisations limited the generalizability of the results; and
selection bias with respect to patients and studyinvestigators preferring non-pharmacological and comple-
mentary therapies could not be excluded. While this study
is the largest European consumer review to-date, the
results still represent a relatively small sample of the over-
all available population.
Conclusions
Consumer reports represent a complementary source of
information on therapeutic effectiveness and side effects,
and may support treatment decisions of patients and
physicians.
The German FMS consumer reports highlight the
importance of self-management strategies and non-
pharmacological treatment options in the long-term
management of FMS, and challenge the strong
recommendations for drug therapy of FMS given by
FMS-guidelines [11-13].
Health webpages should allow the evaluation of non-
pharmacological therapies, and future FMS-consumer
reports should include measures of function to provide a
broader context for study findings.
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